Efficacy in Children & Adultsy

An effective treatment at school^†

Significant symptom improvement reported by teachers of patients with Attention Deficit Hyperactivity Disorder (ADHD).

	Adapted from Data on file.1 Change from baseline versus placebo in the CADS-T total score was the primary efficacy outcomes measure in this trial.

Study design: A 7-week, randomized, double-blind, placebo-controlled trial of Focalin® XR in children and adolescents with ADHD. Patients were randomized to receive either a flexible dose of Focalin® XR (5 mg to 30 mg, n=53) or placebo (n=50) once daily for 7 weeks. During the first 5 weeks, each patient was titrated to an optimal dose and remained on this optimal dose for the last 2 weeks without changes or interruption. Baseline demographics were comparable between the 2 groups. Approximately 40% of patients in both groups had a history of prior stimulant treatment.¹

• Statistically significantly greater improvement in CADS-T total score versus placebo (P<.001)¹

^† Versus untreated placebo patients

An improvement parents can see

Significant improvements reported by parents of patients with ADHD in clinical studies.

	Adapted from Data on file.1

• Statistically significant improvement in CADS-P total score versus placebo (P<.001)¹
• The CADS-P, a parent-rated inattention and hyperactiveimpulsive subscale score, was a secondary efficacy outcomes measure in this clinical trial¹

REFERENCE:

1. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.